Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM)
USD 26.26
(0.23%)
USD 26.26
(0.23%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 9.72 Million USD | 117.91% |
| 2022 | -3.2 Million USD | 31.87% |
| 2021 | -10.14 Million USD | 46.82% |
| 2020 | 2.83 Million USD | 18.59% |
| 2019 | 5.04 Million USD | 170.78% |
| 2018 | -2.73 Million USD | 67.55% |
| 2017 | -10.39 Million USD | 26.64% |
| 2016 | -14.05 Million USD | 0.27% |
| 2015 | -14.21 Million USD | -41.24% |
| 2014 | -10.06 Million USD | -30.99% |
| 2013 | -7.68 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -3.74 Million USD | -196.54% |
| 2024 Q2 | 4.38 Million USD | 157.4% |
| 2023 Q2 | 5.77 Million USD | 48.56% |
| 2023 Q3 | 4.91 Million USD | -14.83% |
| 2023 FY | - USD | 135.64% |
| 2023 Q4 | -1.61 Million USD | -132.78% |
| 2023 Q1 | 3.88 Million USD | 563.72% |
| 2022 Q3 | 723 Thousand USD | -72.73% |
| 2022 Q1 | 3.04 Million USD | 370.69% |
| 2022 Q4 | -838 Thousand USD | -215.91% |
| 2022 FY | - USD | 31.87% |
| 2022 Q2 | 2.65 Million USD | -13.02% |
| 2021 Q4 | -1.12 Million USD | 64.28% |
| 2021 Q2 | 4.77 Million USD | 33.68% |
| 2021 FY | - USD | 46.82% |
| 2021 Q1 | 3.56 Million USD | 19.32% |
| 2021 Q3 | -3.15 Million USD | -166.07% |
| 2020 Q2 | -2.33 Million USD | -1632.59% |
| 2020 Q4 | 2.99 Million USD | 42.43% |
| 2020 FY | - USD | 18.59% |
| 2020 Q1 | -135 Thousand USD | -108.54% |
| 2020 Q3 | 2.1 Million USD | 189.78% |
| 2019 Q3 | 89 Thousand USD | 170.63% |
| 2019 Q4 | 1.58 Million USD | 1675.28% |
| 2019 Q1 | -104 Thousand USD | 90.36% |
| 2019 Q2 | -126 Thousand USD | -21.15% |
| 2019 FY | - USD | 170.78% |
| 2018 Q1 | -1.32 Million USD | 22.19% |
| 2018 Q4 | -1.07 Million USD | -546.11% |
| 2018 FY | - USD | 67.55% |
| 2018 Q2 | -166 Thousand USD | 87.44% |
| 2018 Q3 | -167 Thousand USD | -0.6% |
| 2017 Q3 | -2.29 Million USD | 12.29% |
| 2017 Q2 | -2.61 Million USD | 31.19% |
| 2017 Q1 | -3.79 Million USD | -23.93% |
| 2017 FY | - USD | 26.64% |
| 2017 Q4 | -1.69 Million USD | 25.84% |
| 2016 Q2 | -3.64 Million USD | -1.9% |
| 2016 FY | - USD | 0.27% |
| 2016 Q1 | -3.58 Million USD | 21.06% |
| 2016 Q4 | -3.06 Million USD | 18.69% |
| 2016 Q3 | -3.76 Million USD | -3.26% |
| 2015 Q2 | -3.32 Million USD | -11.3% |
| 2015 Q1 | -2.99 Million USD | -10.08% |
| 2015 Q4 | -4.53 Million USD | -35.09% |
| 2015 FY | - USD | -41.24% |
| 2015 Q3 | -3.35 Million USD | -0.84% |
| 2014 Q4 | -2.71 Million USD | -11.49% |
| 2014 Q1 | -2.33 Million USD | -23.3% |
| 2014 FY | - USD | -30.99% |
| 2014 Q2 | -2.57 Million USD | -10.51% |
| 2014 Q3 | -2.43 Million USD | 5.43% |
| 2013 Q3 | -2.08 Million USD | 6.34% |
| 2013 Q1 | -1.47 Million USD | 0.0% |
| 2013 Q2 | -2.22 Million USD | -51.52% |
| 2013 Q4 | -1.89 Million USD | 9.44% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| CannBioRx Life Sciences Corp. | -22.13 Million USD | 143.928% |
| BIMI International Medical Inc. | -15.33 Million USD | 163.39% |
| China Jo-Jo Drugstores, Inc. | 1.22 Million USD | -692.521% |
| Harrow Health, Inc. 8.625% Senior Notes due 2026 | 9.72 Million USD | 0.0% |
| Leafly Holdings, Inc. | -5.73 Million USD | 269.567% |
| Leafly Holdings, Inc. | -5.73 Million USD | 269.567% |
| LifeMD, Inc. | -8.21 Million USD | 218.368% |
| LifeMD, Inc. | -8.21 Million USD | 218.368% |
| TRxADE HEALTH, Inc. | -13.72 Million USD | 170.865% |
| PetMed Express, Inc. | -394 Thousand USD | 2567.766% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 100.086% |